Kinetochem Applies for Bulk Controlled Drugs Manufacturing: Routine Alert
Published Date: 8/25/2026
Notice
Summary
Kinetochem LLC has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
No Economic Impacts Identified for this Document
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-17276, Importer of Controlled Substances Application: Biopharmaceutical Research Company
Biopharmaceutical Research Company has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
2026-17285, Importer of Controlled Substances Application: Prof Compounding CTS of Ameri
Prof Compounding CTS of Ameri has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.
2026-17275, Catina Allen, N.P.; Decision and Order
Catina Allen, a nurse practitioner from Indiana, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing to challenge this, so the DEA officially revoked her registration, which expired on June 30, 2026. This means she can’t prescribe or manage controlled drugs anymore, affecting her medical practice and patients.
2026-16665, Exempt Chemical Preparations Under the Controlled Substances Act
The applications for exempt chemical preparations received by the Drug Enforcement Administration between March 1, 2026, and June 30, 2026, as listed below, were accepted for filing and have been approved or denied as indicated. This publication addresses preparations through June 30, 2026, that were not included in previous Federal Register notices, and it does not affect preparations that have been previously published.
Previous / Next Documents
Previous: 2026-17287, Bulk Manufacturer of Controlled Substances Application: Chattem Chemicals
Chattem Chemicals wants to become a big-time maker of certain controlled drugs, including marijuana, amphetamines, and oxycodone. If you have thoughts or concerns, you’ve got until October 26, 2026, to speak up or ask for a hearing. This move could impact drug manufacturing and supply, so keep an eye on the timeline and get involved if you want to!
Next: 2026-17289, United States Global Change Research Program; Availability for Public Comment on the Proposed Amendment to the Fifth National Climate Assessment (NCA5)
OSTP, on behalf of the U.S. Global Change Research Program (USGCRP), announces the availability of a proposed amendment and clarification to the Fifth National Climate Assessment (NCA5) for public comment. The proposed amendment addresses the interpretation and Federal use of NCA5 results that depend materially on RCP8.5, SSP5-8.5, SRES A2, or analogous high-emissions pathways.